Sign In
Buy CSLLY
$16.35
-0.280 (-1.68%)
At Close: Jun 03, 2026
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
10:54pm, Monday, 12'th Feb 2024
Strong CSL Behring portfolio growth especially Ig FINANCIAL HIGHLIGHTS 4 Revenue $8.05 billion, up 11% at CC3 NPAT $1.90 billion 1, up 17% NPAT $1.94 billion 1 at CC3, up 20% NPATA $2.02 billion 1,2
KING OF PRUSSIA, Pa. , Feb. 11, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and
KING OF PRUSSIA, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the results
Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
08:00am, Tuesday, 16'th Jan 2024
Findings show that convenience of treatment and flexibility of administration, such as at-home treatment options, are of high importance to patients KING OF PRUSSIA, Pa. , Jan. 16, 2024 /PRNewswire/ -
CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
08:00am, Wednesday, 03'rd Jan 2024
- Hizentra® is the #1 immune globulin prescribed for Primary Immunodeficiency (PI) in the U.S.- Hizentra is the first and only subcutaneous immune globulin (SCIg) treatment approved for C
KING OF PRUSSIA, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the publicat
CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance
02:47pm, Thursday, 14'th Dec 2023
These regulatory milestones bring CSL one step closer to delivering on our promise to patients with a first-in-class recombinant monoclonal antibody for people living with HAE, a community CSL has bee
HEMGENIX® is the first and only gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia B and to show sustained efficacy and safety at three years post-tr
Exclusive Partner in Japan, Meiji Seika Pharma advances regulatory approval This historic approval of the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine underscores CSL's pro
Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
02:00am, Friday, 24'th Nov 2023
Iron Deficiency Day unites a strong global coalition raising awareness on the serious health impact of iron deficiency and iron deficiency anemia1 This year, the spotlight is on the importance of earl
CSL Limited: Positive Capital Return And Earnings Growth Expectations
04:38pm, Friday, 17'th Nov 2023
CSL Limited might possibly embark on a new share buyback plan in the future, when its financial leverage ratio is reduced. CSL Limited is committed to allocating 10%-11% of its sales to R&D investment
CSL and uniQure Win 2023 Prix Galien USA Award
10:00am, Friday, 27'th Oct 2023
HEMGENIX®, the first and only FDA-approved gene therapy for adults with hemophilia B, wins for Best Product for Rare/Orphan Diseases KING OF PRUSSIA, Pa. and LEXINGTON, Mass.
CSL Limited (CSLLY) Q4 2023 Earnings Call Transcript
02:37am, Tuesday, 15'th Aug 2023
CSL Limited (OTCQX:CSLLY) Q4 2023 Earnings Conference Call August 14, 2023 9:00 PM ET Company Participants Mark Dehring - Head of Investor Relations Paul McKenzie - Chief Executive Officer Joy Linton
Biotech firm CSL's full-year profit rises on higher plasma collections
07:00pm, Monday, 14'th Aug 2023
Australia's CSL reported an annual profit on Tuesday that rose 8% as higher plasma collections helped the biotech company counter the impact of currency fluctuations and higher costs.
New Strong Sell Stocks for August 14th
08:39am, Monday, 14'th Aug 2023
AGO, BATL and CSLLY have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2023.
